Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more
Strides Pharma Science Limited (STAR) - Total Liabilities
Latest total liabilities as of September 2025: ₹37.18 Billion INR
Based on the latest financial reports, Strides Pharma Science Limited (STAR) has total liabilities worth ₹37.18 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Strides Pharma Science Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Strides Pharma Science Limited Competitors by Total Liabilities
The table below lists competitors of Strides Pharma Science Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ronglian Group Ltd
SHE:002642
|
China | CN¥1.39 Billion |
|
A-Zenith Home Furnishings Co Ltd
SHG:603389
|
China | CN¥904.28 Million |
|
Antin Infrastructure Partners
LSE:0AA5
|
UK | €74.38 Million |
|
Ningxia Western Venture Industrial Co Ltd
SHE:000557
|
China | CN¥597.32 Million |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
USA | $1.51 Billion |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
MX:VOLARA
|
Mexico | MX$5.44 Billion |
|
NOS S.G.P.S. S.A
PINK:ZONNF
|
USA | $2.49 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Strides Pharma Science Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Strides Pharma Science Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Strides Pharma Science Limited (2005–2025)
The table below shows the annual total liabilities of Strides Pharma Science Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹34.62 Billion | -8.12% |
| 2024-03-31 | ₹37.68 Billion | -15.62% |
| 2023-03-31 | ₹44.66 Billion | -2.77% |
| 2022-03-31 | ₹45.93 Billion | +9.32% |
| 2021-03-31 | ₹42.01 Billion | +18.10% |
| 2020-03-31 | ₹35.57 Billion | -31.65% |
| 2019-03-31 | ₹52.04 Billion | +32.26% |
| 2018-03-31 | ₹39.35 Billion | -24.95% |
| 2017-03-31 | ₹52.42 Billion | +10.29% |
| 2016-03-31 | ₹47.53 Billion | +259.41% |
| 2015-03-31 | ₹13.22 Billion | +30.10% |
| 2014-03-31 | ₹10.17 Billion | -62.34% |
| 2013-03-31 | ₹26.99 Billion | -33.29% |
| 2012-03-31 | ₹40.46 Billion | +37.72% |
| 2011-03-31 | ₹29.38 Billion | +37.28% |
| 2010-03-31 | ₹21.40 Billion | +23.59% |
| 2009-03-31 | ₹17.32 Billion | -0.47% |
| 2008-03-31 | ₹17.40 Billion | +118.53% |
| 2007-03-31 | ₹7.96 Billion | +35.10% |
| 2006-03-31 | ₹5.89 Billion | +79.15% |
| 2005-03-31 | ₹3.29 Billion | -- |